A large global pharmaceutical company wanted to better understand the product potential of a late-stage, highly targeted pipeline drug candidate for immunotherapy. This drug was indicated for a complex, underserved therapeutic condition.
Viscadia was asked to design and build a custom forecast model spanning all global regions and accommodating key therapeutic and commercial drivers of product performance.
Assessed therapy-area nuances, clinical and commercial drivers of product usage, and shift in treatment paradigms driven by imminent pipeline approvals
Identified and evaluated uptake performances of recent key launches to drive uptake assumptions
Collaborated on the design of qualitative and quantitative PMR, leveraged outcomes to construct forecast assumptions and scenarios
Worked with key stakeholders to define dynamics such as non-promoted usage, combo therapy and competitor events
Customized platform for the product opportunity that allowed for dynamic, comprehensive evaluation of key performance drivers, and enabled scenario comparison and contrasting